遺伝子組換え細胞培養サプリメント市場：製品タイプ、供給源、用途、エンドユーザー別-2025～2030年世界予測

遺伝子組換え細胞培養サプリメント市場の2024年の市場規模は9億5,689万米ドルで、2025年には10億7,976万米ドルに成長し、CAGRは13.13%、2030年には20億706万米ドルに達すると予測されています。

急速に進歩する今日のバイオ医薬品環境において、組換え細胞培養サプリメントは現代のバイオテクノロジーと治療法開発の要となっています。科学技術の革新、生産技術の向上、規制の強化が研究や商業的応用を推進する中、市場は大きな進化を遂げています。組換えサプリメントは現在、細胞の成長をサポートし、一貫した生産品質を確保する上で不可欠なものとなっており、その結果、再生医療、遺伝子治療、ワクチン開発における重要なブレークスルーを加速させています。本レポートでは、市場力学を詳細に調査し、市場勢力に影響を与える技術的進歩と新たな産業動向の両方に焦点を当てています。

組み換えサプリメントは、従来の動物由来やヒト由来の代替品よりも安全性と性能が向上するだけでなく、製造プロセスにおける効率と持続可能性の強化に道を開くものであることを、調査も産業リーダーも同様に認識しています。ここで提供される分析は、包括的なデータと洞察に満ちた解説に裏打ちされており、戦略的意思決定者にとって貴重な資料となっています。市場セグメンテーション、地域動向、主要な産業参入企業を掘り下げることで、このエグゼクティブサマリーは組換え細胞培養サプリメントの現状と将来展望の両方を理解するための基礎を築きました。

組み換え細胞培養サプリメント市場を再定義する変革的シフト

組換え細胞培養サプリメント市場は、その全体像を再構築しつつある変革的な変化を目の当たりにしています。近年、遺伝子工学の進歩と相まって、バイオプロセスにおける画期的な進歩が、従来のサプリメント生産方法から組み換え技術を活用したアプローチへの移行を可能にしました。こうした開発により、製品の一貫性と拡大性に優れ、高品質のバイオ医薬品に対する世界の需要の高まりに対応するために不可欠なものとなっています。

競合セグメントにおける顕著な変化は、持続可能性と倫理的な製造プラクティスへの注目が高まっていることです。規制当局がより厳格なガイドラインや産業標準を施行する中、企業はコンプライアンスを確保しつつ、継続的な技術革新を余儀なくされています。この変化は研究開発への投資の増加にも反映され、製品の純度を高め、製造コストを削減する技術の洗練につながっています。さらに、進化する市場ニーズはセグメント横断的な協力を促し、実験研究と工業生産の統合を推進しています。このような開発により、患者のニーズや技術的期待の変動により敏感に反応するビジネスモデルが可能になりました。

その結果、現在の市場環境は強固なイノベーションによって特徴付けられ、精度、品質、効率はもはやオプションではなく、競合を維持しようと努力する企業にとって不可欠な要件となっています。

市場力学を牽引する主要セグメンテーション洞察

組換え細胞培養サプリメント市場を包括的にセグメンテーションすると、現在の戦略と将来の方向性の両方を形成している重要な洞察の層が明らかになります。製品タイプによる分析では、遺伝子組換えアルブミン、遺伝子組換えアプロチニン、遺伝子組換え成長因子、遺伝子組換えインスリン、遺伝子組換えトランスフェリン、遺伝子組換えトリプシンなど、さまざまな製品について検討します。これらの変異体は、細胞培養プロセスを促進し、最適な製品性能を確保する上で、異なるが相互に関連した役割を果たしています。

動物由来とヒト由来という2つの切り口から市場を検証することで、産業の動向がますますヒトに適合した材料に傾く中、安全性と倫理的配慮へのシフトが浮き彫りになります。市場セグメンテーションの追加層は用途に焦点を当て、市場環境はバイオ医薬品生産、遺伝子治療、幹細胞治療、組織工学に及んでいます。バイオ医薬品製造の中でも、モノクローナル抗体、組換えタンパク質、ワクチンといった専門的な研究セグメントが、用途ベースの需要の多様性と複雑さを裏付けています。

さらに、エンドユーザーを考慮すると、この市場は学術研究機関、受託製造機関、製薬会社とバイオ医薬品会社に対応しています。このような多面的なセグメンテーション戦略により、利害関係者はそれぞれのセグメントや用途セグメントの微妙なニーズに沿った投資やイノベーションを行い、アプローチを調整することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 調査と生産プロセスにおける動物由来でない細胞培養サプリメントの採用増加
    • サステイナブル組み換え細胞培養の代替手段によるワクチン生産のニーズ
    • バイオ医薬品とバイオシミラーの需要増加が遺伝子組換え細胞培養サプリメントを押し上げる
  • 抑制要因
    • 製品の有効性に関する懸念が遺伝子組換え細胞培養サプリメントの需要に影響
  • 機会
    • 幹細胞療法の調査活動の増加により、新たな細胞培養サプリメントの機会が創出される
    • パーソナライズ医療への関心の高まりが効率的な遺伝子組換え細胞培養サプリメントを促進
  • 課題
    • サプライチェーンの混乱と遺伝子組換え細胞培養サプリメントの可用性と品質への影響
• 市場セグメンテーション分析
  • 製品タイプ：ワクチンと治療用タンパク質の製造における組換えアルブミンの利用増加
  • エンドユーザー：学術研究機関における遺伝子組換え細胞培養サプリメントの研究開発活動の拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 遺伝子組換え細胞培養サプリメント市場：製品タイプ別

• イントロダクション
• 組換えアルブミン
• 組み換えアプロチニン
• 組み換え成長因子
• 組換えインスリン
• 組み換えトランスフェリン
• 組み換えトリプシン

第7章 遺伝子組換え細胞培養サプリメント市場：供給源別

• イントロダクション
• 動物由来サプリメント
• ヒト由来サプリメント

第8章 遺伝子組換え細胞培養サプリメント市場：用途別

• イントロダクション
• バイオ医薬品製造
  • モノクローナル抗体
  • 組み換えタンパク質
  • ワクチン
• 遺伝子治療
• 幹細胞療法
• 組織工学

第9章 遺伝子組換え細胞培養サプリメント市場：エンドユーザー別

• イントロダクション
• 学術研究機関
• 契約製造組織
• 製薬・バイオ医薬品企業

第10章 南北アメリカの遺伝子組換え細胞培養サプリメント市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の遺伝子組換え細胞培養サプリメント市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの遺伝子組換え細胞培養サプリメント市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abcam Limited
• Becton, Dickinson and Company
• Bio-Techne Corporation
• Biocon Limited
• BPS Bioscience, Inc.
• Cell Sciences, Inc.
• Corning Incorporated
• Cytiva
• F. Hoffmann-La Roche Ltd.
• FUJIFILM Corporation
• HiMedia Laboratories Pvt Ltd
• InVitria
• Kingfisher BIoTech, Inc.
• Laurus Labs Limited
• Lonza Group Ltd.
• Merck KGaA
• Miltenyi BIoTec B.V. & Co. KG
• Novo Nordisk A/S
• Novozymes A/S
• PELOBIOTECH GmbH
• Repligen Corporation
• Sartorius AG
• STEMCELL Technologies
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Zhuhai Gene-Biocon Biological Technology Co., Ltd.

LIST OF FIGURES

• FIGURE 1. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET MULTI-CURRENCY
• FIGURE 2. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET MULTI-LANGUAGE
• FIGURE 3. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET RESEARCH PROCESS
• FIGURE 4. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET DYNAMICS
• TABLE 7. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT APROTININ, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT TRANSFERRIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT TRYPSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY ANIMAL-DERIVED SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY HUMAN-DERIVED SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 46. CANADA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 50. CANADA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 73. CHINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. CHINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 75. CHINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. CHINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 77. CHINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 78. INDIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 79. INDIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 80. INDIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 82. INDIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 164. ITALY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 165. ITALY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 166. ITALY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. ITALY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 168. ITALY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 184. POLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 185. POLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 186. POLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. POLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 188. POLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 189. QATAR RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 190. QATAR RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 191. QATAR RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. QATAR RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 193. QATAR RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 239. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 240. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET, FPNV POSITIONING MATRIX, 2024

The Recombinant Cell Culture Supplements Market was valued at USD 956.89 million in 2024 and is projected to grow to USD 1,079.76 million in 2025, with a CAGR of 13.13%, reaching USD 2,007.06 million by 2030.

In today's rapidly advancing biopharmaceutical environment, recombinant cell culture supplements have become a cornerstone in modern biotechnology and therapeutic development. The market is experiencing significant evolution as scientific innovations, improved production techniques, and heightened regulatory frameworks drive research and commercial applications. Recombinant supplements are now integral in supporting cell growth and ensuring consistent production quality, which in turn accelerates critical breakthroughs in regenerative medicine, gene therapy, and vaccine development. This report offers a detailed exploration into the market dynamics, highlighting both the technological strides and emerging industry trends that influence market forces.

Researchers and industry leaders alike recognize that recombinant supplements not only offer improved safety and performance over conventional animal- or human-derived alternatives but also pave the way for enhanced efficiency and sustainability in manufacturing processes. The analysis provided herein is backed by comprehensive data and insightful commentary, making it a valuable resource for strategic decision-makers. By delving into market segmentation, regional trends, and key industry players, this executive summary lays the foundation for understanding both current conditions and future prospects within recombinant cell culture supplements.

Transformative Shifts Redefining the Recombinant Cell Culture Supplements Market

The recombinant cell culture supplements market has witnessed transformative shifts that are reshaping its overall landscape. In recent years, breakthroughs in bioprocessing, coupled with advancements in genetic engineering, have enabled a move from traditional supplement production methods to approaches that harness recombinant technologies. These developments have resulted in superior product consistency and scalability, which are essential for meeting the rising global demand for high-quality biopharmaceutical products.

A notable change in the competitive arena is the increasing focus on sustainability and ethical manufacturing practices. As regulatory authorities enforce stricter guidelines and industry standards, companies are compelled to innovate continuously while ensuring compliance. This shift is also reflected in increased investments in research and development, leading to the refinement of techniques that enhance product purity and reduce production costs. Moreover, evolving market needs have prompted cross-disciplinary collaboration, driving integration between experimental research and industrial production. Such developments have allowed for adaptive business models that are more responsive to fluctuations in patient needs and technological expectations.

Consequently, the current market environment is marked by robust innovation where precision, quality, and efficiency are no longer optional but vital imperatives for companies striving to maintain a competitive edge.

Key Segmentation Insights Driving Market Dynamics

A comprehensive segmentation of the recombinant cell culture supplements market reveals layers of critical insights that are shaping both current strategies and future directions. Analysis based on product type examines a spectrum of offerings, including recombinant albumin, recombinant aprotinin, recombinant growth factors, recombinant insulin, recombinant transferrin, and recombinant trypsin. These variants serve distinct yet interconnected roles in facilitating cell culture processes and ensuring optimum product performance.

Examining the market through the lens of source has provided a dichotomy between animal-derived and human-derived supplements, highlighting shifts toward safety and ethical considerations as industry trends lean increasingly towards human-compatible materials. An additional layer of segmentation focuses on application, where the market landscape spans biopharmaceutical production, gene therapy, stem cell therapy, and tissue engineering. Within biopharmaceutical production, specialized study segments-monoclonal antibodies, recombinant proteins, and vaccines-underscore the diversity and complexity of application-based demand.

Moreover, when considering end-users, the market caters to academic and research institutes, contract manufacturing organizations, and pharmaceutical as well as biopharmaceutical companies. This multifaceted segmentation strategy enables stakeholders to tailor their approach, ensuring that investments and innovations align with the nuanced needs of each segment and application area.

Based on Product Type, market is studied across Recombinant Albumin, Recombinant Aprotinin, Recombinant Growth Factors, Recombinant Insulin, Recombinant Transferrin, and Recombinant Trypsin.

Based on Source, market is studied across Animal-derived Supplements and Human-derived Supplements.

Based on Application, market is studied across Biopharmaceutical Production, Gene Therapy, Stem Cell Therapy, and Tissue Engineering. The Biopharmaceutical Production is further studied across Monoclonal Antibodies, Recombinant Proteins, and Vaccines.

Based on End-Users, market is studied across Academic & Research Institutes, Contract Manufacturing Organizations, and Pharmaceutical & Biopharmaceutical Companies.

Global Regional Analysis in Recombinant Cell Culture Supplements

The global reach of recombinant cell culture supplements makes regional analysis a critical component of the market overview. The Americas have emerged as a vibrant hub for research and development, driven by well-established infrastructure and significant funding dedicated to biotechnology. This region is characterized by an impressive network of academic institutions and innovative private sector ventures that collectively drive market growth.

Europe, Middle East & Africa present a diverse set of opportunities where a balanced mix of regulatory rigor and investment in emerging technologies has fostered a robust market environment. Countries within this cluster are uniquely positioned to leverage historical expertise with current advances in cell culture supplements, ensuring that innovations translate effectively into practical applications.

Asia-Pacific continues to reveal rapid expansion driven by both technological adoption and cost-effective manufacturing capabilities. The region's dynamic economic landscape, coupled with a focus on scalability and operational efficiency, is contributing significantly to the global market share while propelling future growth prospects. This regional insight underscores the varied yet interconnected nature of market development across continents, reflecting a global tapestry of technological progress and market evolution.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Industry Leaders Shaping the Supplement Innovation

The recombinant cell culture supplements arena is enriched by contributions from globally recognized industry leaders whose innovative portfolio continues to redefine market parameters. Esteemed companies such as Abcam Limited, Becton, Dickinson and Company, and Bio-Techne Corporation have been at the forefront in advancing product development. Other notable entities including Biocon Limited, BPS Bioscience, Inc., Cell Sciences, Inc., and Corning Incorporated have consistently provided robust solutions that address the technical challenges associated with cell culture and bioprocessing.

Key players like Cytiva, F. Hoffmann-La Roche Ltd., FUJIFILM Corporation, and HiMedia Laboratories Pvt Ltd add to the vibrant competitive landscape, supported by pioneering research and significant investments in technology. Furthermore, organizations including InVitria, Kingfisher Biotech, Inc., Laurus Labs Limited, and Lonza Group Ltd. continue to fuel progress through strategic partnerships and R&D collaborations. The impressive list is further bolstered by Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Novo Nordisk A/S, and Novozymes A/S, among others, all of which contribute unique strengths and market insights.

These key companies not only drive innovations within the field but also foster an environment where continued excellence in research and product quality reinforces the overall market trajectory. Their collective efforts are instrumental in setting benchmarks and encouraging industry-wide best practices that resonate across the global biopharmaceutical landscape.

The report delves into recent significant developments in the Recombinant Cell Culture Supplements Market, highlighting leading vendors and their innovative profiles. These include Abcam Limited, Becton, Dickinson and Company, Bio-Techne Corporation, Biocon Limited, BPS Bioscience, Inc., Cell Sciences, Inc., Corning Incorporated, Cytiva, F. Hoffmann-La Roche Ltd., FUJIFILM Corporation, HiMedia Laboratories Pvt Ltd, InVitria, Kingfisher Biotech, Inc., Laurus Labs Limited, Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Novo Nordisk A/S, Novozymes A/S, PELOBIOTECH GmbH, Repligen Corporation, Sartorius AG, STEMCELL Technologies, Takara Bio Inc., Thermo Fisher Scientific Inc., and Zhuhai Gene-Biocon Biological Technology Co., Ltd.. Guidance for Strategic Leadership in the Recombinant Supplement Sector

For industry leaders aiming to capitalize on the potential of recombinant cell culture supplements, adopting a multi-pronged strategic approach is essential. Firstly, it is crucial to foster investment in advanced research and development that centers on enhancing the purity and consistency of recombinant products. This includes leveraging state-of-the-art technologies and integrating robust quality control measures into every phase of product development and manufacturing.

Secondly, companies should prioritize the expansion of their market presence by tapping into emerging regional opportunities. A strategic focus on regions like Asia-Pacific, along with sustained engagement in Americas and Europe, Middle East & Africa, can result in diversified revenue streams and favorable market positioning. Collaborations between multinational entities and local regulatory bodies are also necessary to refine product offerings in accordance with regional standards and consumer expectations.

Thirdly, refining segmentation strategies can empower businesses to tailor solutions that effectively meet diverse end-user needs. By harnessing data-driven insights that consider variations in product type, source, application, and end-user profiles, decision-makers can develop more targeted and innovative product lines. Finally, leaders must remain agile and responsive to regulatory changes and technological advancements, ensuring that strategic pivots are well-aligned with the evolving market landscape.

Conclusion: Charting a Future of Sustainable Growth

In summary, the recombinant cell culture supplements market is positioned at the intersection of cutting-edge technology and dynamic global trends. The analysis presented herein demonstrates that evolving methodologies, strategic segmentation, and the unparalleled contributions of industry leaders are collectively propelling the market toward unprecedented growth. The integration of advanced biotechnology into supplement production not only addresses current challenges but also paves the way for innovations that will transform therapeutic development across various applications.

This comprehensive overview underscores that a nuanced understanding of market segmentation-ranging from product type to source, application, and end-user demographics-is essential for navigating the complexities of this sector. Furthermore, regional insights provide a holistic view of how local innovations and market dynamics can drive global trends. The synthesis of these insights reassures stakeholders that sound investments in research and infrastructure, along with strategic agility, will be instrumental in maintaining momentum in a rapidly evolving marketplace.

Embracing these strategic imperatives will ensure that the market continues to thrive, setting a course for sustainable growth and long-term success.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing adoption of animal-free cell culture supplements in research and production processes
    • 5.1.1.2. Needs in vaccine production with sustainable recombinant cell culture alternatives
    • 5.1.1.3. Rising demand for biologics and biosimilars boosting recombinant cell culture supplements
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns surrounding product efficacy affecting demand for recombinant cell culture supplements
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing research activities in stem cell therapy creating opportunities for novel cell culture supplements
    • 5.1.3.2. Growing interest in personalized medicine boosts efficient recombinant cell culture supplements
  • 5.1.4. Challenges
    • 5.1.4.1. Supply chain disruptions and their effect on availability and quality of recombinant cell culture supplements
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Increasing utilization of recombinant albumin for the production of vaccines and therapeutic proteins
  • 5.2.2. End-Users: Expanding research & development activities for recombinant cell culture supplements in academic and research institutes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Recombinant Cell Culture Supplements Market, by Product Type

• 6.1. Introduction
• 6.2. Recombinant Albumin
• 6.3. Recombinant Aprotinin
• 6.4. Recombinant Growth Factors
• 6.5. Recombinant Insulin
• 6.6. Recombinant Transferrin
• 6.7. Recombinant Trypsin

7. Recombinant Cell Culture Supplements Market, by Source

• 7.1. Introduction
• 7.2. Animal-derived Supplements
• 7.3. Human-derived Supplements

8. Recombinant Cell Culture Supplements Market, by Application

• 8.1. Introduction
• 8.2. Biopharmaceutical Production
  • 8.2.1. Monoclonal Antibodies
  • 8.2.2. Recombinant Proteins
  • 8.2.3. Vaccines
• 8.3. Gene Therapy
• 8.4. Stem Cell Therapy
• 8.5. Tissue Engineering

9. Recombinant Cell Culture Supplements Market, by End-Users

• 9.1. Introduction
• 9.2. Academic & Research Institutes
• 9.3. Contract Manufacturing Organizations
• 9.4. Pharmaceutical & Biopharmaceutical Companies

10. Americas Recombinant Cell Culture Supplements Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Recombinant Cell Culture Supplements Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Cell Culture Supplements Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Croda Pharma's innovative solution enhances cell culture performance with Super Refined Poloxamer 188 launch
  • 13.3.2. Axio BioPharma expands with new protein manufacturing services in Madison to meet biopharma demand
  • 13.3.3. Core Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins
  • 13.3.4. Strategic partnership between Nucleus Biologics and Core Biogenesis to revolutionize sustainable cell culture media with plant-based recombinant proteins
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abcam Limited
• 2. Becton, Dickinson and Company
• 3. Bio-Techne Corporation
• 4. Biocon Limited
• 5. BPS Bioscience, Inc.
• 6. Cell Sciences, Inc.
• 7. Corning Incorporated
• 8. Cytiva
• 9. F. Hoffmann-La Roche Ltd.
• 10. FUJIFILM Corporation
• 11. HiMedia Laboratories Pvt Ltd
• 12. InVitria
• 13. Kingfisher Biotech, Inc.
• 14. Laurus Labs Limited
• 15. Lonza Group Ltd.
• 16. Merck KGaA
• 17. Miltenyi Biotec B.V. & Co. KG
• 18. Novo Nordisk A/S
• 19. Novozymes A/S
• 20. PELOBIOTECH GmbH
• 21. Repligen Corporation
• 22. Sartorius AG
• 23. STEMCELL Technologies
• 24. Takara Bio Inc.
• 25. Thermo Fisher Scientific Inc.
• 26. Zhuhai Gene-Biocon Biological Technology Co., Ltd.